Biotech Stocks To Keep An Eye On - July 3rd

Thermo Fisher Scientific, AbbVie, Lixte Biotechnology, Danaher, and Moderna are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that apply biological processes—such as genetic engineering, cell culture, and molecular biology—to develop drugs, diagnostics, and other life-sciences products. Because these firms often involve lengthy, expensive research and strict regulatory approval, their stock prices can be highly volatile but also offer significant growth potential if clinical trials or product launches succeed. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of TMO stock traded down $0.05 during mid-day trading on Thursday, hitting $427.71. 739,719 shares of the stock traded hands, compared to its average volume of 1,965,058. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The firm has a market cap of $161.46 billion, a price-to-earnings ratio of 25.08, a price-to-earnings-growth ratio of 2.24 and a beta of 0.77. The company's 50-day simple moving average is $409.06 and its 200-day simple moving average is $481.30. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $627.88.

Read Our Latest Research Report on TMO

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

NYSE:ABBV traded down $1.04 during mid-day trading on Thursday, reaching $189.72. 1,356,904 shares of the stock were exchanged, compared to its average volume of 6,229,249. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. The business has a fifty day moving average price of $187.12 and a 200 day moving average price of $188.23. AbbVie has a 1-year low of $163.52 and a 1-year high of $218.66. The firm has a market capitalization of $335.11 billion, a PE ratio of 80.68, a PEG ratio of 1.26 and a beta of 0.48.

Read Our Latest Research Report on ABBV

Lixte Biotechnology (LIXT)

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.

Shares of Lixte Biotechnology stock traded up $0.72 on Thursday, reaching $2.74. 62,223,543 shares of the company were exchanged, compared to its average volume of 639,638. The firm has a market capitalization of $7.33 million, a price-to-earnings ratio of -1.88 and a beta of 0.31. Lixte Biotechnology has a fifty-two week low of $0.64 and a fifty-two week high of $4.21. The stock has a fifty day moving average price of $1.22 and a 200-day moving average price of $1.55.

Read Our Latest Research Report on LIXT

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

NYSE DHR traded up $0.67 on Thursday, hitting $203.17. 761,729 shares of the stock were exchanged, compared to its average volume of 3,492,986. The company's 50-day moving average price is $195.39 and its two-hundred day moving average price is $207.80. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. Danaher has a 52-week low of $171.00 and a 52-week high of $281.70. The company has a market capitalization of $145.40 billion, a price-to-earnings ratio of 39.41, a P/E/G ratio of 2.82 and a beta of 0.77.

Read Our Latest Research Report on DHR

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of MRNA traded up $0.53 during mid-day trading on Thursday, reaching $30.81. The company's stock had a trading volume of 4,791,227 shares, compared to its average volume of 8,659,526. The company has a market cap of $11.92 billion, a price-to-earnings ratio of -3.53 and a beta of 1.84. The business has a fifty day moving average of $26.59 and a 200 day moving average of $31.60. Moderna has a 1 year low of $23.15 and a 1 year high of $129.39.

Read Our Latest Research Report on MRNA